New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Novel biomarkers for PARP inhibitor trials for children with cancer
What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.
Identifying whether children with ALCL, ALK- also harbour other genetic changes in their tumours, and what affect this has on how their cancer progresses. This knowledge can help to guide clinicians about how best to treat children with this rarer sub-form of lymphoma.
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
The Little Princess Trust Knowledge Bank of Wilms Tumour
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas